

NOAH Compendium

Printed from NOAH Compendium (<https://hub21.community.librios.com>). (c) Copyright NOAH Compendium 2026. All Rights Reserved.

Date: Wednesday, February 18, 2026 12:30

[MSD Animal Health UK Limited](#)

Telephone:01908 685685 (Customer Support Centre)

Website:www.msd-animal-health.co.uk

Email:vet-support.uk@msd.com

Vivitonin® tablets for dogs

Species:Dogs

Therapeutic indication:Pharmaceuticals: Cardiovascular and respiratory preparations

Active ingredient:Propentofylline

Product:Vivitonin® 50 mg tablets and Vivitonin® 100 mg tablets

Product index:Vivitonin® 50 mg and 100 mg tablets

Incorporating:Vivitonin® 50 mg tablets for dogs

Vivitonin® 100 mg tablets for dogs

Qualitative and quantitative composition

Vivitonin 50 mg tablets:

Each tablet contains:

Active substance:

Propentofylline 50 mg

Film coating:

Iron oxide yellow (E172) 0.125 mg

Titanium dioxide (E171) 0.359 mg

Vivitonin 100 mg tablets:

Each tablet contains:

Active substance:

Propentofylline 100 mg

Film coating:

NOAH Compendium

Iron oxide yellow (E172) 0.258 mg

Titanium dioxide (E171) 0.856 mg

For the full list of excipients, see section “Pharmaceutical particulars”.

Pharmaceutical form

Vivitonin 50 mg tablets: Ochre, biconvex, round film-coated tablets, quarter scored on one side, and debossed on the other side with “K50”.

Vivitonin 100 mg tablets: Ochre, biconvex and oblong film-coated tablets with a breaking line on one side and “K100” debossed on both sides of the breaking line.

Clinical particulars

Target Species

Dogs.

Indications for use

For improvement in dullness, lethargy and overall demeanour in dogs. The veterinary medicinal product is particularly useful in older dogs, where it may increase willingness to exercise and exercise tolerance.

Contraindications

Do not administer to pregnant bitches or breeding animals.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Special warnings for each target species

None.

Special precautions for use

Specific diseases (e.g. kidney disease) should be treated accordingly.

In the case of renal failure, the dose should be reduced.

Consideration should be given to rationalising the medication of dogs already receiving treatment for congestive heart failure or bronchial disease.

Operator warnings

Care should be taken to avoid accidental ingestion.

Wash hands after use.

Adverse Reactions

Dogs:

NOAH Compendium

Rare (1 to 10 animals / 10,000 animals treated):

Vomiting¹; Allergic reaction (e.g., U

¹ Particularly at the commencement of therapy.

² Necessitates discontinuation of treatment.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

Use during pregnancy or lactation

Pregnancy:

Do not use in pregnant bitches. The safety of the veterinary medicinal product has not been established during pregnancy.

Fertility:

Do not use in breeding animals.

Interactions

None known.

Amounts to be administered and administration route

Vivitonin 50 mg tablets:

Oral use.

Half a tablet per 5 kg bodyweight twice a day (equivalent to 6-10 mg propentofylline per kg bodyweight per day).

Dogs of less than 5 kg may receive a quarter of a tablet twice a day. Dogs of more than 20 kg can be given Vivitonin 100 mg tablets.

The tablets can be administered directly onto the back of the dog's tongue or can be mixed in a small ball of food and should be administered at least 30 minutes before feeding.

Divide the tablets in halves and quarters with a knife or with a tablet splitter.

Vivitonin 100 mg tablets:

Oral use.

Half a tablet per 10 kg body weight twice a day.

The 100 mg tablets should not be quartered. More accurate dosing may be achieved using a combination of Vivitonin 100 mg and Vivitonin 50 mg tablets. Dogs of less than 20 kg can be given Vivitonin 50 mg tablets.

NOAH Compendium

The tablets can be administered directly onto the back of the dog's tongue or can be mixed in a small ball of food and should be administered at least 30 minutes before feeding.

Divide the tablets in halves with a knife or with a tablet splitter.

Overdose

Symptoms of cardiac and cerebral overstimulation have been observed. In such cases, animals should be treated symptomatically.

Withdrawal periods

Not applicable.

Pharmacological particulars

ATCvet code: QC04AD90.

Pharmacodynamic properties

Propentofylline has been shown to increase blood flow, particularly of the heart and skeletal muscle. It also increases the blood flow of the brain and therefore its oxygen supply, without increasing the brain's glucose demand. It has a modest positive chronotropic effect and a marked positive inotropic effect. In addition, it has been shown to have an anti-arrhythmic effect in dogs with myocardial ischemia and a bronchodilator action equivalent to that of aminofylline.

Propentofylline inhibits platelet aggregation and improves the flow properties of erythrocytes.

It has a direct effect on the heart and reduces peripheral vascular resistance thereby lowering cardiac load.

Pharmacokinetic particulars

After oral administration, propentofylline is rapidly and completely absorbed and quickly distributed into the tissues. Maximum plasma levels are reached by 15 minutes following oral dosing in dogs.

The half-life is approximately 30 minutes and the bioavailability of the parent compound is approximately 30%.

There are a number of effective metabolites and biotransformation takes place mainly in the liver.

80-90% of propentofylline is excreted in the form of metabolites via the kidneys. The rest is eliminated with the faeces.

There is no bioaccumulation.

Pharmaceutical particulars

Excipients

Excipients

NOAH Compendium

Lactose monohydrate

Maize starch

Crospovidone

Talc

Magnesium stearate

Silica, colloidal anhydrous

Film Coating:

Hypromellose

Talc

Titanium dioxide (E171)

Iron oxide yellow (E172)

Macrogol 8000

Major incompatibilities

None known.

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Special precautions for storage

Do not store above 25°C. Store in a dry place.

Keep blister packs in outer carton.

Special precautions for storage

Do not store above 25 °C. Store in a dry place.

Return any half tablets to the original packaging.

Keep the blister packs in the outer carton.

Immediate packaging

Vivitonin 50 mg tablets:

Polyvinyl chloride/aluminium foil blister packs of 2 x 30 tablets.

Pack size:

Cardboard box containing 60 tablets, presented in 2 blister strips of 30 tablets.

NOAH Compendium

Vivitonin 100 mg tablets:

Polyvinyl chloride/aluminium foil blister packs of 6 x 10 tablets.

Pack size:

Cardboard box containing 60 tablets, presented in 6 blister strips of 10 tablets.

Disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

Marketing Authorisation Holder (if different from distributor)

Intervet International B.V. represented by MSD Animal Health UK Ltd.

Marketing Authorisation Number

UK:

50 mg tab Vm 06376/4074

100 mg tab Vm 06376/4078

Significant changes

Date of the first authorisation or date of renewal

Vivitonin 50 mg tablets: 17 September 1991 Vivitonin 100 mg tablets: 30 September 1994

Date of revision of the text

October 2025.

Any other information

For animal treatment only. Keep out of the sight and reach of children.

Legal category

Legal category:POM-V

GTIN

GTIN description:Vivitonin 50mg 2x30tab:

GTIN:08713184044174

GTIN description:Vivitonin 100mg 6x10tab:

GTIN:08713184044426

